{"generic":"Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine","drugs":["Adacel","Boostrix","Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine"],"mono":{"0":{"id":"928835-s-0","title":"Generic Names","mono":"Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine"},"1":{"id":"928835-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928835-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Vaccination for diphtheria, pertussis, and tetanus:<\/b> 0.5 mL IM single dose; use Boostrix(R) for 18 years or older, Adacel(TM) for age 18 to 64 years<\/li><li><b>Vaccination for diphtheria, pertussis, and tetanus:<\/b> (pregnancy) single dose during each pregnancy, preferably during 27 to 36 weeks of gestation<\/li><\/ul>"},"1":{"id":"928835-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Vaccination for diphtheria, pertussis, and tetanus:<\/b> 0.5 mL IM single dose at age 11 to 12 years (guideline dose); (10 years or older) 0.5 mL IM single dose (manufacturer dose)<\/li><li><b>Vaccination for diphtheria, pertussis, and tetanus:<\/b> (pregnant adolescent) single dose during each pregnancy, preferably during 27 to 36 weeks of gestation<\/li><\/ul>"},"3":{"id":"928835-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Vaccination for diphtheria, pertussis, and tetanus<br\/>"}}},"3":{"id":"928835-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928835-s-3-9","title":"Contraindications","mono":"<ul><li>allergic reaction, severe (eg, anaphylaxis), to a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis antigen-containing vaccine or to any component of the vaccine<\/li><li>encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of pertussis-containing vaccine and not attributable to another cause<\/li><\/ul>"},{"id":"928835-s-3-10","title":"Precautions","mono":"<ul><li>arthus-type hypersensitivity occurring after a previous dose of tetanus toxoid; avoid administering any tetanus toxoid-containing vaccine more frequently than every 10 years<\/li><li>brachial neuritis may occur with tetanus toxoid-containing vaccines<\/li><li>Guillain-Barr  syndrome within 6 weeks of previous tetanus toxoid-containing vaccination; carefully evaluate risk\/benefit prior to administration<\/li><li>immunosuppression, including patients receiving immunosuppressive therapy; immune response may be altered<\/li><li>latex sensitivity; Adacel(R) and Boostrix(R) tip caps and rubber plunger of the Boostrix(R) prefilled syringes contain natural latex rubber<\/li><li>neurological disorders, progressive or unstable (eg, progressive encephalopathy, uncontrolled epilepsy, cerebrovascular events, or acute encephalopathic conditions); may result in diagnostic confusion between manifestations of underlying illness and possible vaccination adverse events; consider deferring vaccination until condition resolves or is stabilized<\/li><li>syncope, possibly accompanied by transient neurological signs (eg, visual disturbance, paresthesia, tonic-clonic limb movements), has been reported; have procedures in place to manage possible syncopal reactions and to prevent falling injury following administration<\/li><li>report suspected adverse events to vaccine adverse effects reporting (VAERS) at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"928835-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928835-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928835-s-4","title":"Drug Interactions","sub":{"1":{"id":"928835-s-4-14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"},"2":{"id":"928835-s-4-15","title":"Moderate","mono":"<ul><li>Chloramphenicol (probable)<\/li><li>Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent (established)<\/li><\/ul>"}}},"5":{"id":"928835-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain (pediatric, 75.3% to 77.8%; adult, 21.5% to 65.7%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal symptom (pediatric, 26%; adult, 7.6% to 15.9%)<\/li><li><b>Neurologic:<\/b>Fatigue (pediatric, 30.2% to 37%; adult, 12.5% to 28.1%), Headache (pediatric, 43.1% to 43.7%; adult, 11.5% to 33.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Seizure<\/li><\/ul>"},"6":{"id":"928835-s-6","title":"Drug Name Info","sub":[{"id":"928835-s-6-17","title":"US Trade Names","mono":"<ul><li>Adacel<\/li><li>Boostrix<\/li><\/ul>"},{"id":"928835-s-6-18","title":"Synonyms","mono":"<ul><li>Tdap Vaccine<\/li><li>Tdap - Diphtheria, Tetanus, and Acellular Pertussis Booster Vaccine<\/li><li>Diphtheria, Tetanus, and Acellular Pertussis Booster Vaccine<\/li><\/ul>"},{"id":"928835-s-6-19","title":"Class","mono":"Vaccine<br\/>"},{"id":"928835-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},{"id":"928835-s-6-21","title":"Generic Availability","mono":"No<br\/>"}]},"7":{"id":"928835-s-7","title":"Mechanism Of Action","mono":"<ul><li>Diphtheria toxoid component helps reduce the risk of developing diphtheria and induces the development of neutralizing antibodies to the diphtheria toxin. The vaccine protects immunized persons for at least 10 years and enables vaccine recipients to develop only a mild form of the disease in case they do develop diphtheria.<\/li><li>Tetanus toxoid component stimulates the development of neutralizing antibodies to tetanus toxin and protects adequately immunized persons against tetanus for at least 10 years.<\/li><li>Acellular pertussis vaccine component protects adequately immunized persons against Bordetella pertussis. The exact mechanism of action of immunity to pertussis is unknown.<\/li><\/ul>"},"9":{"id":"928835-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>IM only; do not give subQ, IV, or intradermally<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>do not mix with any other vaccine in the same vial or syringe<\/li><li>shake vial or syringe well<\/li><li>inject into the deltoid muscle of the upper arm<\/li><li>have procedures in place to manage syncopal reactions and to prevent falling injury<\/li><\/ul><\/li><\/ul>"},"10":{"id":"928835-s-10","title":"Monitoring","mono":"signs and symptoms of hypersensitivity to acellular pertussis vaccines<br\/>"},"11":{"id":"928835-s-11","title":"How Supplied","mono":"<ul><li><b>Adacel<\/b><br\/>Intramuscular Suspension: (Pertussis Vaccine, Acellular - Reduced Diphtheria Toxoid - Tetanus Toxoid) 2.5 MCG\/0.5 ML-2 Lf U\/0.5 ML-5 Lf U\/0.5 ML<br\/><\/li><li><b>Boostrix<\/b><br\/>Intramuscular Suspension: (Pertussis Vaccine, Acellular - Reduced Diphtheria Toxoid - Tetanus Toxoid) 18.5 MCG\/0.5 ML-2.5 Lf U\/0.5 ML-5 Lf U\/0.5 ML<br\/><\/li><\/ul>"},"13":{"id":"928835-s-13","title":"Clinical Teaching","mono":"This drug may cause injection site reactions (pain, swelling, erythema, fever), headache, tiredness, nausea, and diarrhea.<br\/>"}}}